<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331981</url>
  </required_header>
  <id_info>
    <org_study_id>L_8968</org_study_id>
    <nct_id>NCT00331981</nct_id>
  </id_info>
  <brief_title>Amisulpride in Schizophrenic Patients</brief_title>
  <official_title>Study of the Efficacy and Safety After Long-Term Treatment With Amisulpride in Schizophrenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary purpose:

        -  To find out how effective is long term treatment with amisulpride on the positive and
           negative symptoms in schizophrenic patients

        -  To find out how safe is long term treatment with amisulpride in schizophrenic patients

      Secondary purpose:

        -  To find out how effective is long term treatment with amisulpride on the quality of life
           in schizophrenic patients

        -  To find out how effective is long term treatment with amisulpride on the cognitive
           function in schizophrenic patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS scores</measure>
    <time_frame>at every visit</time_frame>
  </primary_outcome>
  <enrollment>138</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed as schizophrenia or schizophrenic disorder according to DSM-IV

          -  Patients who need new anti-psychotic drugs or need to change the medication due to
             aggravations of symptoms or recurrence

        Exclusion Criteria:

          -  Patients with positive symptoms in whom the disorder does not correspond to
             schizophrenic criteria. (e.g, schizoaffective disorder)

          -  Patients hypersensitive to the active ingredient or to other ingredients of the study
             drug

          -  Prolactin-dependant tumors, pituitary gland prolactinomas and breast cancer

          -  Pheochromocytoma or Parkinson's disease

          -  Pregnancy or breast feeding

          -  Current or recently withdrawn from drug abuse or alcoholism

          -  Chronic renal failure and other internal or surgical disease which physician decides
             will be worsened by trial medication or that will affect the metabolism or effects of
             the trial medication

          -  Patients with previous histories and clinical improvement was not seen in spite of
             treatment with 2 anti-psychotics for over 8 weeks

          -  Slow heart rate of &lt;55bpm, low blood potassium level, congenital prolongation of the
             QT interval

          -  Current treatment with a drug likely to cause markedly slow heart rate(&lt;55bpm), low
             blood potassium level, slowing of intercardiac condition or prolongation of the QT
             interval

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Sik Lee, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2006</study_first_submitted>
  <study_first_submitted_qc>May 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2006</study_first_posted>
  <last_update_submitted>April 8, 2008</last_update_submitted>
  <last_update_submitted_qc>April 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sultopride</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

